164 In the index

Sermorelin SERM

A hormone-releasing medication that was FDA-approved for diagnosing and treating growth hormone deficiency before being discontinued as a brand-name product, though it's still available through compounding pharmacies. Earlier approved-use studies support that it triggers the body's own growth hormone release, though it's weaker and shorter-acting than newer options.

Also known as GRF 1-29, Sermorelina, Sermoreline, Sermorelinum, 89243S03TE, CHEBI:9118, Groliberin, hGHRH(1-29)NH2

Effects Build muscle Hormonal

Routes Subcutaneous

Legal status Prescription drug

WADA Banned at all times

Molecular Structure of C₁₄₉H₂₄₆N₄₄O₄₂S

Drag to rotate · scroll to zoom

Chemistry

Formula: C149H246N44O42S
Molar mass: 3357.9
CAS: 86168-78-7
PubChem CID: 16132413
IUPAC name: (3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
InChIKey: WGWPRVFKDLAUQJ-MITYVQBRSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 200-300 mcg/day

Reported range 200-500 mcg/day

Route Subcutaneous injection

Frequency Once daily, typically before bed

Duration 3-6 month course, per anti-aging clinic protocols

Was previously FDA-approved (as Geref) for diagnostic use before being discontinued by its manufacturer; now sold mainly through compounding pharmacies and anti-aging clinics for off-label GH-support use, without an approved standardized product.

Where this comes from Historical FDA-approved product labeling (discontinued); clinic/compounding-pharmacy literature

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.